论文部分内容阅读
普卢利沙星是由日本新药公司与明智制果公司共同开发的新氟喹诺酮类抗菌药,在日本及某些欧洲国家被批准用于治疗下呼吸道感染及慢性支气管炎急性发作。近年来,人们对其在除上述临床适应证之外的其他系统感染方面进行了较广泛的临床研究。结果表明,普卢利沙星可能是对付细菌性前列腺炎和旅行性腹泻的一个具有前景的药物,而其在降低膀胱癌治疗中卡介苗相关毒性方面的潜在预防作用也值得关注。尽管如此,本品在上述领域的应用尚需临床研究的进一步证实。
Prulifloxacin, a new fluoroquinolone antibacterial drug jointly developed by Nippon Shokubai and Miyoshi Kogyo, was approved for the treatment of lower respiratory tract infections and acute exacerbation of chronic bronchitis in Japan and certain European countries. In recent years, there has been a broader clinical study of other systemic infections in addition to the above clinical indications. The results indicate that prulifloxacin may be a promising drug against bacterial prostatitis and travel diarrhea, and its potential preventive role in reducing BCG-related toxicity in bladder cancer treatment is also of concern. In spite of this, the application of this product in the above fields still need further confirmation of clinical studies.